Építés alatt – nem éles oldal
Belépés
Befejeződött2. fázis

Effects of Experimental Sleep Disturbances on Receptor Function of Study Drug

A legfontosabb adatok

Ki végzi
Johns Hopkins University
Hol
Baltimore (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Befejeződött
Fázis
2. fázis
Résztvevők
148 fő vett részt
Kezdés
2020. nov. 11.
Befejezés
2025. aug. 31.
A vizsgálat típusa
Beavatkozással járó, 3 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Sleep Fragmentation
  • Within-Subject test of blinded study medication (stimulant, benzodiazepine, opioid, cannabinoid, over-the-counter pain medication, or placebo)
  • Sleep Continuity Disruption
  • Undisturbed Sleep
A regiszteradat frissítve
2025. szeptember 24.

Ki vehet részt

Életkor
18 év – 48 év
Nem
Nők és férfiak
Egészséges önkéntesek
Részt vehetnek

A regiszter feltételei, szó szerint

Mind a 23 feltétel megnézéseKevesebb

Ki vehet részt

  • Healthy, 18-48 year olds meeting criteria for Normal Sleep
  • Sleep phase within 21:00 and 08:00
  • Total sleep time >6.5 and ≤8.5 hours/night; sleep efficiency ≥85%
  • Non-smokers/nicotine users
  • Low caffeine users (≤ 2 cups, q.d.)
  • Life-time history of exposure to opioids, appropriately prescribed for pain

Ki nem vehet részt

  • Positive toxicology screen for opioids or recreational drugs
  • Had exposure to ionizing radiation that in combination with the study's estimated radiation exposure would result in a cumulative exposure, exceeding recommended limits
  • Lifetime history of chronic pain
  • Meet clinical criteria for a sleep disorder
  • Significant central nervous system disease (e.g., lupus, multiple sclerosis)
  • Cognitive impairment, brain injury or history of closed head injury with loss of consciousness over 3 mins
  • Other significant medical or psychiatric morbidity within 6 months or lifetime history of bipolar disorder, psychotic disorder, seizure disorder
  • Any contraindicated medical condition
  • Lifetime history of alcohol or substance used disorder
  • Clinically significant abnormal complete blood count, hepatic, renal or metabolic panel
  • BMI >35
  • Acute pain
  • Use in the last three months of the following: antidepressants, neuroleptics, sedative hypnotics, isoniazid, glucocorticoids, psychostimulants, opioids
  • Pregnant or lactating women
  • Significant preadmission psychological distress
  • Embedded metal objects or fragments or electronic devices in the head or body that would present a risk during MRI
  • Unable to tolerate the scanning environment/ claustrophobia

Helyszínek itt: Egyesült Államok

  • Johns Hopkins School of MedicineBaltimore, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

The overall goal of this project is to determine whether common sleep disturbance patterns, sleep continuity disturbance (SCD) and Sleep Fragmentation (SF), alter cerebral study drug receptor availability, drug-based analgesia, and drug abuse liability. The investigators specifically aim to: 1) evaluate whether experimental SCD and/or SF alter resting or pain-evoked receptor binding potential in brain regions associated with pain inhibition; 2) examine whether SCD and/or SF alters the analgesic response and abuse liability profile of a study medication; and 3) determine whether receptor binding potentials in brain regions of interest are associated with study medication analgesia and abuse liability. The investigators will also evaluate the extent to which associations differ by sleep condition or sex.

A vizsgálat 3 csoportja

  • Sleep Continuity DisruptionA vizsgált kezelés

    The Sleep Continuity Disruption condition will be conducted on two consecutive nights. An 8-hour sleep opportunity period will be disturbed by several forced awakenings at random intervals during which no sleep is permitted.

    Kezelés: Within-Subject test of blinded study medication (stimulant, benzodiazepine, opioid, cannabinoid, over-the-counter pain medication, or placebo) és Sleep Continuity Disruption

  • Sleep FragmentationA vizsgált kezelés

    The Sleep fragmentation condition will be conducted on two consecutive nights. Subjects are provided an 8-hour sleep opportunity during which their sleep will be disturbed by microarousals that simulate sleep apnea.

    Kezelés: Sleep Fragmentation és Within-Subject test of blinded study medication (stimulant, benzodiazepine, opioid, cannabinoid, over-the-counter pain medication, or placebo)

  • Undisturbed SleepMár használt kezelés, összehasonlításként

    An 8-hour period of undisturbed sleep is permitted on each night.

    Kezelés: Within-Subject test of blinded study medication (stimulant, benzodiazepine, opioid, cannabinoid, over-the-counter pain medication, or placebo) és Undisturbed Sleep

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Effects of Experimental Sleep Disruption and Fragmentation on Study Drug Receptor Function, Receptor Agonist Analgesia, and Abuse Liability
A regiszteradat frissítve
2025. szeptember 24.